$NEO
NEOGENOMICS INC Stock $neo

$neo Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000107718322000081 Filed on May 09, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q4
Revenue	$125.1M	$117.2M	$125.7M
YoY Change	2.75%	1.42%	-0.21%
Cost Of Revenue	$81.13M	$78.94M	$80.48M
YoY Change	18.03%	6.73%	17.48%
Gross Profit	$43.95M	$38.23M	$45.26M
YoY Change	-17.07%	-8.04%	-21.29%
Gross Profit Margin	35.14%	32.63%	35.99%
Selling, General & Admin	$70.13M	$82.55M	$67.50M
YoY Change	-2.41%	52.23%	43.0%
% of Gross Profit	159.59%	215.91%	149.14%
Research & Development	$8.626M	$7.713M	$8.513M
YoY Change	146.81%	214.05%	305.38%
% of Gross Profit	19.63%	20.17%	18.81%
Depreciation & Amortization	$17.02M	$8.395M	$16.86M
YoY Change	59.05%	25.67%	75.28%
% of Gross Profit	38.72%	21.96%	37.26%
Operating Expenses	$82.40M	$90.26M	$84.49M
YoY Change	9.34%	59.24%	63.1%
Operating Profit	-$38.45M	-$52.03M	-$39.23M
YoY Change	71.91%	244.4%	-788.23%
Interest Expense	-$926.0K	$1.301M	-$1.707M
YoY Change	-202.66%	10.54%	-22.41%
% of Operating Profit
Other Income/Expense, Net	-$405.0K	$168.0K	-$930.0K
YoY Change	-336.84%	-103.46%	-122.14%
Pretax Income	-$41.03M	-$53.16M	-$44.20M
YoY Change	-155.88%	151.49%	-681.63%
Income Tax	-$5.730M	-$3.753M	-$2.445M
% Of Pretax Income
Net Earnings	-$35.30M	-$49.41M	-$41.76M
YoY Change	-146.53%	123.42%	-371.16%
Net Earnings / Revenue	-28.23%	-42.17%	-33.21%
Basic Earnings Per Share
Diluted Earnings Per Share	-$284.5K	-$399.6K	-$340.6K
COMMON SHARES
Basic Shares Outstanding	124.8M shares	123.6M shares	123.1M shares
Diluted Shares Outstanding	124.1M shares	123.6M shares

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$466.0M	$481.4M	$515.4M
YoY Change	-18.5%	-40.02%	73.97%
Cash & Equivalents	$283.6M	$305.9M	$316.8M
Short-Term Investments	$182.3M	$175.5M	$198.6M
Other Short-Term Assets	$21.22M	$20.69M	$8.189M
YoY Change	151.92%	342.63%	79.78%
Inventory	$21.86M	$23.84M	$23.40M
Prepaid Expenses		$14.34M	$12.35M
Receivables	$113.2M	$110.8M	$112.1M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$622.3M	$651.1M	$681.5M
YoY Change	-13.79%	-30.93%	51.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$211.0M	$108.9M	$109.5M
YoY Change	88.06%	15.51%	27.47%
Goodwill		$527.1M	$527.1M
YoY Change		149.7%	149.72%
Intangibles		$433.8M	$442.3M
YoY Change		267.05%	266.61%
Long-Term Investments			$0.00
YoY Change			-100.0%
Other Assets	$6.095M	$6.600M	$7.168M
YoY Change	-20.58%	25.17%	59.18%
Total Long-Term Assets	$1.170B	$1.178B	$1.188B
YoY Change	-0.4%	113.61%	120.21%
TOTAL ASSETS
Total Short-Term Assets	$622.3M	$651.1M	$681.5M
Total Long-Term Assets	$1.170B	$1.178B	$1.188B
Total Assets	$1.792B	$1.830B	$1.870B
YoY Change	-5.49%	22.43%	89.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.85M	$20.48M	$17.92M
YoY Change	-26.92%	8.26%	-28.22%
Accrued Expenses	$59.06M	$54.85M	$62.98M
YoY Change	-15.22%	28.15%	52.5%
Deferred Revenue		$6.119M	$5.192M
YoY Change		53.28%	28.87%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$410.0K	$621.0K	$1.135M
YoY Change	-78.57%	-70.43%
Total Short-Term Liabilities	$82.67M	$82.07M	$87.23M
YoY Change	-16.61%	21.14%	19.2%
LONG-TERM LIABILITIES
Long-Term Debt	$533.9M	$533.2M	$532.6M
YoY Change	0.45%	0.39%	214.93%
Other Long-Term Liabilities	$86.05M	$14.14M	$14.02M
YoY Change	2166.78%	281.47%	245.71%
Total Long-Term Liabilities	$619.9M	$672.5M	$674.3M
YoY Change	-4.45%	15.36%	205.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$82.67M	$82.07M	$87.23M
Total Long-Term Liabilities	$619.9M	$672.5M	$674.3M
Total Liabilities	$748.6M	$754.5M	$761.5M
YoY Change	0.09%	15.96%	158.98%
SHAREHOLDERS EQUITY
Retained Earnings		-$64.25M	-$14.84M
YoY Change		124.61%	106.5%
Common Stock		$1.142B	$1.124B
YoY Change		30.93%	60.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.044B	$1.075B	$1.108B
YoY Change
Total Liabilities & Shareholders Equity	$1.792B	$1.830B	$1.870B
YoY Change	-5.49%	22.43%	89.19%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	-$35.30M	-$49.41M	-$41.76M
YoY Change	-146.53%	123.42%	-371.16%
Depreciation, Depletion And Amortization	$17.02M	$8.395M	$16.86M
YoY Change	59.05%	25.67%	75.28%
Cash From Operating Activities	-$17.00M	-$29.04M	-$19.78M
YoY Change	1122.73%	-1414.03%	-430.15%
INVESTING ACTIVITIES
Capital Expenditures	-$10.29M	$8.219M	-$11.99M
YoY Change	-51.78%	-48.08%	4.14%
Acquisitions
YoY Change
Other Investing Activities	$4.020M	$20.27M	$2.404M
YoY Change	-100.93%	-114.6%	-113.86%
Cash From Investing Activities	-$6.274M	$12.05M	-$9.583M
YoY Change	-98.62%	-107.79%	-66.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$6.403M
YoY Change		144.67%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.011M	$6.057M	2.460M
YoY Change	-99.51%	-98.85%	-70.25%
NET CHANGE
Cash From Operating Activities	-17.00M	-$29.04M	-19.78M
Cash From Investing Activities	-6.274M	$12.05M	-9.583M
Cash From Financing Activities	1.011M	$6.057M	2.460M
Net Change In Cash	-22.26M	-$10.93M	-26.90M
YoY Change	-91.1%	-102.93%	84.37%
FREE CASH FLOW
Cash From Operating Activities	-$17.00M	-$29.04M	-$19.78M
Capital Expenditures	-$10.29M	$8.219M	-$11.99M
Free Cash Flow	-$6.702M	-$37.26M	-$7.789M
YoY Change	-133.58%	173.54%	-144.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001077183
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-35756
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	NEOGENOMICS, INC.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	74-2897368
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	9490 NeoGenomics Way,
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Fort Myers,
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33912
CY2022Q1	dei	City Area Code CityAreaCode	(239)
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	768-0600
CY2022Q1	dei	Security12b Title Security12bTitle	Common stock ($0.001 par value)
CY2022Q1	dei	Trading Symbol TradingSymbol	NEO
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	124758179	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	305896000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	316827000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	175534000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	198563000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	110796000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	112130000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	23840000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	23395000	USD
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	14341000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	12354000	USD
CY2022Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	0	USD
CY2021Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	10050000	USD
CY2022Q1	us-gaap	Other Assets Current OtherAssetsCurrent	20693000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	8189000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	651100000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	681508000	USD
CY2022Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	116254000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	109952000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	108942000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	109465000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	101955000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	102197000	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	433835000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	442325000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	527115000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	527115000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6600000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7168000	USD
CY2022Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	1178447000	USD
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1188270000	USD
CY2022Q1	us-gaap	Assets Assets	1829547000	USD
CY2021Q4	us-gaap	Assets Assets	1869778000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	20481000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17921000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	32320000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	38304000	USD
CY2022Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	16571000	USD
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	17796000	USD
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	621000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1135000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5958000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6884000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6119000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5192000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	82070000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	87232000	USD
CY2022Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	533189000	USD
CY2021Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	532483000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	73434000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	72289000	USD
CY2022Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	51709000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	55475000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14141000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	14022000	USD
CY2022Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	672473000	USD
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	674269000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	754543000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	761501000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	124722215	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	124722215	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	124107500	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	124107500	shares
CY2022Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	125000	USD
CY2021Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	124000	USD
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1142133000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1123628000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3009000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-638000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64245000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14837000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	1075004000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1108277000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1829547000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1869778000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	117169000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	115533000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	78937000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	73959000	USD
CY2022Q1	us-gaap	Gross Profit GrossProfit	38232000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	41574000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	66248000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	40476000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7713000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2456000	USD
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	16299000	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13749000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	90260000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	56681000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-52028000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15107000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	1301000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	1177000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	168000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4854000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53161000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21138000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3753000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	976000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-49408000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-22114000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.40
CY2021Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.19
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.40
CY2021Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.19
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	123630000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116199000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123630000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116199000	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-49408000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-22114000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2371000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-160000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2371000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-160000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-51779000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22274000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	1108277000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	971000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-1049000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6480000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	249000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11855000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2371000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-49408000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	1075004000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	694294000	USD
CY2021Q1	neo	Adjustments To Additional Paid In Capital Decrease From Purchase Of Calls Related To Convertible Debt AdjustmentsToAdditionalPaidInCapitalDecreaseFromPurchaseOfCallsRelatedToConvertibleDebt	29291000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1024000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-614000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2239000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	218500000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	242000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	241000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2412000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-160000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-22114000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	843714000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-49408000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-22114000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	8395000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	6680000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8490000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2458000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	12103000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2653000	USD
CY2022Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	2653000	USD
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	1862000	USD
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	661000	USD
CY2021Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	593000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	45000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	43000	USD
CY2022Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	0	USD
CY2021Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-5024000	USD
CY2022Q1	neo	Receivable With Imputed Interest Non Consolidated Affiliates ReceivableWithImputedInterestNonConsolidatedAffiliates	0	USD
CY2021Q1	neo	Receivable With Imputed Interest Non Consolidated Affiliates ReceivableWithImputedInterestNonConsolidatedAffiliates	209000	USD
CY2022Q1	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	2048000	USD
CY2021Q1	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	0	USD
CY2022Q1	neo	Polymerase Chain Reaction Testing Exit Costs Covid19 PolymeraseChainReactionTestingExitCostsCOVID19	0	USD
CY2021Q1	neo	Polymerase Chain Reaction Testing Exit Costs Covid19 PolymeraseChainReactionTestingExitCostsCOVID19	6061000	USD
CY2022Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	1126000	USD
CY2021Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	548000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1334000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3921000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	445000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2845000	USD
CY2022Q1	neo	Increase Decrease In Prepaid Construction IncreaseDecreaseInPrepaidConstruction	0	USD
CY2021Q1	neo	Increase Decrease In Prepaid Construction IncreaseDecreaseInPrepaidConstruction	823000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2044000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	794000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-9902000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-6538000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29040000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2210000	USD
CY2022Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	16167000	USD
CY2021Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	137776000	USD
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	36438000	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	13919000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8219000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15831000	USD
CY2022Q1	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	0	USD
CY2021Q1	us-gaap	Payments To Fund Longterm Loans To Related Parties PaymentsToFundLongtermLoansToRelatedParties	15000000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12052000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-154688000	USD
CY2022Q1	neo	Repayments Of Equipment And Other Finance Obligation RepaymentsOfEquipmentAndOtherFinanceObligation	346000	USD
CY2021Q1	neo	Repayments Of Equipment And Other Finance Obligation RepaymentsOfEquipmentAndOtherFinanceObligation	1091000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6403000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2617000	USD
CY2022Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2021Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	334410000	USD
CY2022Q1	neo	Payments Of Premiums For Capped Call Confirmations PaymentsOfPremiumsForCappedCallConfirmations	0	USD
CY2021Q1	neo	Payments Of Premiums For Capped Call Confirmations PaymentsOfPremiumsForCappedCallConfirmations	29291000	USD
CY2022Q1	neo	Proceeds From Equity Offering Net ProceedsFromEquityOfferingNet	0	USD
CY2021Q1	neo	Proceeds From Equity Offering Net ProceedsFromEquityOfferingNet	218290000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6057000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	524935000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10931000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	372457000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	316827000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	250632000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	305896000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	623089000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	305896000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	611970000	USD
CY2022Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	11119000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	305896000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	623089000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	442000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	41000	USD
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2021Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-49000	USD
CY2022Q1	neo	Noncash Gain On Sale Of Property Included In Accounts Receivable Net NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet	12098000	USD
CY2021Q1	neo	Noncash Gain On Sale Of Property Included In Accounts Receivable Net NoncashGainOnSaleOfPropertyIncludedInAccountsReceivableNet	0	USD
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1061000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2081000	USD
CY2021Q1	neo	Polymerase Chain Reaction Testing Exit Costs Covid19 PolymeraseChainReactionTestingExitCostsCOVID19	6100000	USD
CY2021Q1	neo	Polymerase Chain Reaction Testing Write Offs Covid19 PolymeraseChainReactionTestingWriteOffsCOVID19	5300000	USD
CY2021Q1	neo	Polymerase Chain Reaction Testing General And Administrative Expenses Covid19 PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19	800000	USD
CY2022Q1	neo	Polymerase Chain Reaction Testing General And Administrative Expenses Covid19 PolymeraseChainReactionTestingGeneralAndAdministrativeExpensesCOVID19	0	USD
CY2021Q4	neo	Social Security Tax Employer Deferral Cares Act SocialSecurityTaxEmployerDeferralCARESAct	3000000	USD
CY2022Q1	neo	Social Security Tax Employer Deferral Cares Act SocialSecurityTaxEmployerDeferralCARESAct	3000000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company prepares its Consolidated Financial Statements in conformity with GAAP. These principles require management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the Consolidated Financial Statements. Actual results and outcomes may differ from management’s estimates, judgments and assumptions. Significant estimates, judgments and assumptions used in these Consolidated Financial Statements include, but are not limited, to those related to revenues, accounts receivable and related allowances, contingencies, useful lives and recovery of long-term assets and intangible assets, income taxes and valuation allowances, stock-based compensation, business combinations, and impairment analysis of goodwill. These estimates, judgments, and assumptions are reviewed periodically and the effects of material revisions in estimates are reflected on the Consolidated Financial Statements prospectively from the date of the change in estimate.</span></div>
CY2022Q1	neo	Asset Held For Sale Square Feet Of Facility Owned AssetHeldForSaleSquareFeetOfFacilityOwned	43560	sqft
CY2021Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	10100000	USD
CY2022Q1	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	12100000	USD
CY2022Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	2000000	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2700000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	178808000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	USD
CY2022Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3275000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	175534000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	199464000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	22000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	923000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	198563000	USD
CY2022Q1	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	400000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	600000	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
CY2021Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	108392000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	67142000	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	0	USD
CY2022Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	175534000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	104711000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	93852000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	0	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	198563000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	527115000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	527115000	USD
CY2022Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	501380000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	67545000	USD
CY2022Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	433835000	USD
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	501380000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	59055000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	442325000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8490000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2458000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	25389000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	33899000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	33899000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	33798000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	33485000	USD
CY2022Q1	neo	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	259918000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	420388000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12100000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2961195	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	25.46
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1218481	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	25.03
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	471609	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	13.70
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	747269	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	29.56
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2960798	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	26.11
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1343021	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	19.37
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.016
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	9.98
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	12500000	USD
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y2M12D
CY2022Q1	us-gaap	Accelerated Share Repurchase Program Adjustment AcceleratedShareRepurchaseProgramAdjustment	5900000	USD
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2022Q1	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	Collection of consideration the Company expects to receive typically occurs within 30 to 60 days of billing for commercial insurance, Medicare and other governmental and self-pay payers and within 60 to 90 days of billing for client payers.
CY2022Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1643000	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1738000	USD
CY2022Q1	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	261000	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	236000	USD
CY2022Q1	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	1904000	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	1974000	USD
CY2022Q1	us-gaap	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	168000	USD
CY2021Q4	us-gaap	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	109000	USD
CY2022Q1	us-gaap	Capitalized Contract Cost Net Noncurrent CapitalizedContractCostNetNoncurrent	972000	USD
CY2021Q4	us-gaap	Capitalized Contract Cost Net Noncurrent CapitalizedContractCostNetNoncurrent	882000	USD
CY2022Q1	us-gaap	Capitalized Contract Cost Gross CapitalizedContractCostGross	1140000	USD
CY2021Q4	us-gaap	Capitalized Contract Cost Gross CapitalizedContractCostGross	991000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6119000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	5192000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1081000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	917000	USD
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	7200000	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	6109000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3100000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2700000	USD
CY2022Q1	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	100000	USD
CY2021Q1	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	200000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	117169000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	115533000	USD
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-49408000	USD
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22114000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	123630000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	116199000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123630000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116199000	shares
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.40
CY2021Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.19
CY2022Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.40
CY2021Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.19
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	117169000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	115533000	USD
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	78937000	USD
CY2021Q1	us-gaap	Cost Of Revenue CostOfRevenue	73959000	USD
CY2022Q1	us-gaap	Gross Profit GrossProfit	38232000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	41574000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	66248000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	40476000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7713000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2456000	USD
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	16299000	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13749000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	90260000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	56681000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-52028000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15107000	USD
CY2022Q1	us-gaap	Interest Expense InterestExpense	1301000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	1177000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	168000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4854000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53161000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21138000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3753000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	976000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-49408000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-22114000	USD

Files In Submission

Name	View Source	Status
0001077183-22-000081-index-headers.html	Edgar Link	pending
0001077183-22-000081-index.html	Edgar Link	pending
0001077183-22-000081.txt	Edgar Link	pending
0001077183-22-000081-xbrl.zip	Edgar Link	pending
a03312022neo-ex311.htm	Edgar Link	pending
a03312022neo-ex312.htm	Edgar Link	pending
a03312022neo-ex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
neo-20220331.htm	Edgar Link	pending
neo-20220331.xsd	Edgar Link	pending
neo-20220331_cal.xml	Edgar Link	unprocessable
neo-20220331_def.xml	Edgar Link	unprocessable
neo-20220331_htm.xml	Edgar Link	completed
neo-20220331_lab.xml	Edgar Link	unprocessable
neo-20220331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tetraultagreement.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NEO
NEOGENOMICS INC Stock $neo

2022 Q2 Form 10-Q Financial Statement

#000107718322000081 Filed on May 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEO NEOGENOMICS INC Stock $neo

2022 Q2 Form 10-Q Financial Statement

#000107718322000081 Filed on May 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEO
NEOGENOMICS INC Stock $neo